Anti-ADAMTS13 antibody [EPR6132]
- RabMAb
- Recombinant
- What is this?
Be the first to review this product! Submit a review
|
(2 Publications)
Rabbit Recombinant Monoclonal ADAMTS13 antibody. Suitable for WB, Flow Cyt (Intra) and reacts with Human samples. Cited in 2 publications.
View Alternative Names
C9orf8, UNQ6102/PRO20085, ADAMTS13, A disintegrin and metalloproteinase with thrombospondin motifs 13, ADAM-TS 13, ADAM-TS13, ADAMTS-13, von Willebrand factor-cleaving protease, vWF-CP, vWF-cleaving protease
- Flow Cyt (Intra)
Supplier Data
Flow Cytometry (Intracellular) - Anti-ADAMTS13 antibody [EPR6132] (AB177940)
Intracellular flow cytometric analysis of permeabilized A549 cells labeling ADAMTS13 with ab177940at 1/100 dilution.
- WB
Supplier Data
Western blot - Anti-ADAMTS13 antibody [EPR6132] (AB177940)
All lanes:
Western blot - Anti-ADAMTS13 antibody [EPR6132] (ab177940) at 1/1000 dilution
Lane 1:
Human fetal liver lysate at 10 µg
Lane 2:
A549 cell lysate at 10 µg
Lane 3:
HepG2 lysate at 10 µg
Predicted band size: 154 kDa
false
Related conjugates and formulations (1)
-
Anti-ADAMTS13 antibody [EPR6132] - BSA and Azide free
Reactivity data
Product details
Patented technology
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free batch production
For more information, read more on recombinant antibodies.
Properties and storage information
Form
Purification technique
Storage buffer
Shipped at conditions
Appropriate short-term storage duration
Appropriate short-term storage conditions
Appropriate long-term storage conditions
Aliquoting information
Storage information
Supplementary information
This supplementary information is collated from multiple sources and compiled automatically.
Biological function summary
ADAMTS13 plays a role in regulating the size and function of von Willebrand factor (vWF) ensuring proper hemostatic balance. The enzyme prevents the accumulation of ultra-large vWF multimers which can lead to spontaneous platelet aggregation and thrombus formation. Although ADAMTS13 acts independently its function is closely linked to the dynamics of vWF in response to vascular injury. Properly functioning ADAMTS13 aids in maintaining normal blood flow by preventing unnecessary clot formation in the bloodstream.
Pathways
ADAMTS13 is critical in the coagulation and hemostatic pathways. It operates by modulating the activity of vWF which plays an essential role in platelet adhesion and aggregation forming part of the coagulation cascade. A significant relationship exists between ADAMTS13 and vWF in these pathways as the protease controls vWF multimer size directly impacting clot formation. In the context of hemostatic balance ADAMTS13 intersects with factors like thrombin and fibrinogen which further contribute to clotting processes.
Product protocols
- Visit the General protocols
- Visit the Troubleshooting
Target data
Publications (2)
Recent publications for all applications. Explore the full list and refine your search
Frontiers in cardiovascular medicine 9:1059124 PubMed36794234
2023
Applications
Unspecified application
Species
Unspecified reactive species
Scientific reports 8:7859 PubMed29777164
2018
Applications
Unspecified application
Species
Unspecified reactive species
Product promise
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com